12:00 AM
Aug 20, 2007
 |  BioCentury  |  Emerging Company Profile

AvidBiotics: Poking holes in resistance

Broad-spectrum antibiotics contribute to the spread of multi-drug resistance among diverse bacteria and cause side effects through undesired damage to healthy bacterial flora. To address these concerns, AvidBiotics Corp. is developing Avidocin therapeutics, which are engineered R-type pyocins designed to kill specific bacteria while remaining insensitive to resistance mechanisms.

Pyocins are large bactericidal proteins produced by some bacteria to serve as natural defenses against other bacteria.

R-type pyocins are derived from Pseudomonas aeruginosa. Other naturally occurring pyocins include S-types and F-types. According to the company, the R-types are probably the only pyocins with sufficient potency and specificity to be engineered for a clinical application.

An R-type pyocin consists of a contractile sheath surrounding a core tube, with six bacteriophage-like tail fibers attached to the tube's base. R-type pyocins kill target cells by binding at least three tail fibers to a bacterial surface receptor, attaching the tube to the bacterium.

Contraction of...

Read the full 749 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >